The absence of interleukin-10 (IL-10), a potent anti-inflammatory cytokine results in increased immune-mediated demyelination in mice infected with a neurotropic coronavirus (recombinant J2.2-V-1 [rJ2.2]). Here, we examined the therapeutic effects of increased levels of IL-10 at early times after infection by engineering a recombinant J2.2 virus to produce IL-10. We demonstrate that viral expression of IL-10, which occurs during the peak of virus replication and at the site of disease, enhanced survival and diminished morbidity in rJ2.2-infected wild-type B6 and IL-10 ؊/؊ mice. The protective effects of increased IL-10 levels were associated with reductions in microglial activation, inflammatory cell infiltration into the brain, and proinflammatory cytokine and chemokine production. Additionally, IL-10 increased both the frequency and number of Foxp3 ؉ regulatory CD4 T cells in the infected central nervous system. Most strikingly, the ameliorating effects of IL-10 produced during the first 5 days after infection were long acting, resulting in decreased demyelination during the resolution phase of the infection. Collectively, these results suggest that the pathogenic processes that result in demyelination are initiated early during infection and that they can be diminished by exogenous IL-10 delivered soon after disease onset. IL-10 functions by dampening the innate or very early T cell immune response. Further, they suggest that early treatment with IL-10 may be useful adjunct therapy in some types of viral encephalitis.
The anti-inflammatory cytokine interleukin-10 (IL-10) is a pleiotropic cytokine that is produced in abundant quantities during most parasitic, bacterial, viral, and fungal diseases. Until recently, IL-10 was believed to be most important during chronic infections with its expression linked to the development of chronic infections in mice such as those caused by Leishmania major, lymphocytic choriomeningitis virus (LCMV), and Toxoplasma gondii (3, 5, 12, 44) . In these infections, abrogation of IL-10-mediated immunosuppression results in accelerated pathogen clearance, and this is sometimes accompanied by immunopathological disease. IL-10 has also been implicated in pathogen persistence in chronic human infections such as hepatitis C virus (HCV) and Mycobacterium tuberculosis (10, 16) .
Only recently has a role for IL-10 in acute diseases been appreciated. In acute viral infections caused by pathogens such as influenza A virus (IAV), simian virus 5 (SV5), respiratory syncytial virus (RSV), and mouse hepatitis virus (MHV), IL-10 production is maximal at the height of the adaptive inflammatory response, with IL-10 expressed largely by virus-specific CD4 and CD8 T cells (27, 30, 36, 37, 39, 41) . We and others showed that virus-specific IL-10 ϩ CD8 T cells are more activated and cytolytic than are IL-10 Ϫ CD8 T cells responding to the same epitope (39, 41) . IL-10 primarily acts to suppress macrophages and dendritic cell (DC) function by inhibiting expression of major histocompatibility complex (MHC) class II and costimulatory molecules such as CD80/CD86 and production of proinflammatory cytokines and chemokines, including IL-12 (31) . IL-10 also has direct effects on T cells, inhibiting activation and cytokine expression. Production of IL-10 by highly activated virus-specific T cells raises the possibility that IL-10 functions via both autocrine and paracrine signaling to limit inflammation during acute phases of the disease. Nevertheless, the importance of IL-10's anti-inflammatory effects in acute disease is not firmly established, since it continues to be expressed during the resolution phases of an infection. IL-10 diminished disease in mice infected with a variant of MHV, strain JHMV (J2.2-V-1) that causes mild acute encephalitis and chronic demyelinating encephalomyelitis (4, 38) . Demyelination in these mice is largely mediated by the immune response (43, 45) . Infection of IL-10 Ϫ/Ϫ mice resulted in increased morbidity and mortality and augmented demyelination compared to wild-type mice (43, 45) . To determine IL-10's role during the early stages of infection, we engineered recombinant J2.2-V-1 (rJ2.2) expressing IL-10 (rJ2.2-IL-10) or encoding a nonfunctional version of the gene (rJ2.2-⌬IL-10). Infection with rJ2.2-IL-10 resulted in expression of high levels of IL-10 at the site of infection, with levels that became undetectable as the virus was cleared. Since IL-10 has a half-life of approximately 2 h (26), cytokine levels track with virus clearance, making this a useful system for evaluating the role of exogenously added IL-10 during the peak phase of the infection. We show that early viral expression of IL-10 enhanced survival and diminished chronic demyelination in rJ2.2-infected B6 and IL-10 Ϫ/Ϫ mice.
MATERIALS AND METHODS
Mice. Specific-pathogen-free, 6-week-old C57BL/6 (B6) mice were purchased from the National Cancer Institute (Bethesda, MD). IL-10 Ϫ/Ϫ (B6.129P2-Il10tm1Cgn/J) mice were bred in the animal facility of the University of Iowa. After viral inoculation, mice were examined and weighed daily. Clinical evalua-tion was based on the following scoring system: 0, asymptomatic; 1, limp tail; 2, wobbly gait with righting difficulty; 3, hind limb weakness and extreme righting difficulty; 4, hind limb paralysis; 5, moribund. All animal studies were approved by the University of Iowa Animal Care and Use Committee.
Recombinant viruses. Targeted recombination was used to generate recombinant virus, as previously described (21, 29) . We introduced the Il10 gene, produced synthetically (GENEART, Burlingame, CA), into rJ2.2, replacing part of open reading frame 4 (ORF4) as described previously ( Fig. 1A) (17, 18) . Insertion of exogenous genetic material into ORF4 does not affect virulence (35) . For a control, another construct was made in which the start codon (ATG) was mutated to ATC (boldface nucleotide changed), and Arg (AGA) and Gln (CAG) residues at positions 13 and 19 of the Il10 gene were mutated to termination codons (TGA) and (TAG), respectively, using overlapping extension PCR (designated pJ2.2.⌬IL-10). Recombinant viruses were propagated, and the titers of the viruses were determined on 17Cl-1 and HeLa-MHVR cells, respectively (17, 18, 21, 35) . Sequence analysis prior to use in further studies confirmed the presence of the introduced genes. To control for any unwanted mutations that might have occurred during the process of targeted recombination, multiple isolates of each virus were developed (three rJ2.2-IL-10 isolates and two rJ2.2-⌬IL-10 isolates). Identical results were obtained with the different isolates. Subsequently, most in vivo experiments used single isolates of rJ2.2-IL-10 and rJ2.2-⌬IL-10. Mice were inoculated intracerebrally (i.c.) with 1,000 or 500 PFU in 30 l of Dulbecco modified Eagle medium (DMEM). To confirm retention of IL-10 or deletion of IL-10, RNA was analyzed by reverse transcription-PCR (RT-PCR) using virus-specific primers that flanked the inserted sequence, as described previously (17, 18) . A 608-nucleotide product is expected if the insert is present.
Growth kinetics and expression of IL-10 in tissue culture. 17Cl-1 cells were infected with virus at a multiplicity of infection of 1 PFU per cell. Samples were harvested at the indicated times. Viral titers were determined on HeLa-MHVR cells, and IL-10 expression was determined by enzyme-linked immunosorbent assay (ELISA).
Antibodies and flow cytometric analyses. All antibodies were purchased from BD-Pharmingen (San Diego, CA) unless indicated otherwise below. Natural killer (NK) cells were CD45 ϩ CD3 Ϫ NK1.1 ϩ . Macrophages were CD45 ϩ CD11b ϩ Ly6C ϩ Ly6G Ϫ . Neutrophils were CD45 ϩ CD11b ϩ Ly6C ϩ Ly6G ϩ . Microglia were CD45 int CD11b ϩ . MHC class II was detected with fluorescein isothiocyanate (FITC)-conjugated anti-I-A/I-E antibodies from eBioscience (San Diego, CA). Microglial activation was assessed by measuring the expression of CD40 and CD80 (eBioscience) and CD86 (Biolegend, San Diego, CA). For detection of regulatory T cells (Tregs), cells were stained with peridinin chlorophyll protein (PerCP)-conjugated anti-CD4 monoclonal antibody (MAb). After permeabilization and fixation, cells were stained with phycoerythrin (PE)-conjugated anti-Foxp3 antibody or PE-conjugated isotype control rat IgG2a MAb as described by the manufacturer (eBiosciences). For detection of intracellular cytokine expression, CD8 or CD4 T cells were stimulated for 5 h with 1 M peptide S510 (spanning residues S510 to 518 of the surface [S] glycoprotein) or 5 M peptide M133 (spanning residues M133 to 147 of the transmembrane [M] protein) in the presence of 1 l/ml Golgiplug (BD Pharmingen) and antigenpresenting cells (APCs) (CHB3 cells, H-2D b , I-A b ). Intracellular gamma interferon (IFN-␥) and IL-10 expression was detected following fixation and permeabilization (BD Pharmingen). Cells were then incubated with anti-CD16/ CD32-biotin and anti-CD4 or anti-CD8, followed by avidin-PerCP. Results are shown after gating on CD16/CD32-negative cell populations. Cells were analyzed using a FACSCalibur (BD Biosciences).
Preparation of central nervous system (CNS) mononuclear cells. Brain mononuclear cells were isolated as described previously (48) . Briefly, tissue was dis- Mononuclear cells were isolated by passing the tissue through a 70-m cell strainer and centrifugation after resuspension in 30% Percoll (Pharmacia, Uppsala, Sweden). ELISA. Brain tissue samples were homogenized directly into 50 mM Tris, 150 mM NaCl, 5 mM EDTA, 1 mM Na 3 VO 4 , 1% NP-40, and a protease inhibitor cocktail (Complete protease inhibitor cocktail; Roche, Mannheim, Germany) as described previously (40) . IL-10, IL-6, tumor necrosis factor (TNF), and chemokine (C-C motif) ligand 2 (CCL2) ELISAs were performed using reagents and protocols provided by the manufacturer (eBioscience). Samples were plated in duplicate.
Quantification of demyelination. For examination of demyelination, 8-m zinc formalin-fixed sections were stained with luxol fast blue (LFB) and counterstained with hematoxylin and eosin. Images of stained spinal cord sections were digitalized using an Optiphot charge-coupled camera attached to a Leitz diaplan light microscope (Leica Microsystems, Wetzlar, Germany). Quantification of demyelination was performed in a blind manner as previously described (46) .
qRT-PCR. Brain RNA was extracted using TRIzol reagent (Invitrogen/Life Technologies, Carlsbad, CA) and reverse transcribed using Superscript II (Invitrogen) according to the manufacturer's instructions. Cytokine mRNA levels were quantified by quantitative reverse transcription-PCR (qRT-PCR) using SYBR green (SA Biosciences, Frederick, MD). The primers used for qRT-PCR were as follows: IL-10 F (F for forward), 5Ј-GCGTCGTGATTAGCGATGAT G-3Ј; IL-10 R (R for reverse), 5Ј-CTCGAGCAAGTCTTTCAGTCC-3Ј; TNF F, 5Ј-TCAGCCGATTTGCTATCTCA-3Ј; TNF R, 5Ј-CGGACTCCGCAAAGTC TAAG-3Ј; CCL2 F, 5Ј-AGCACCAGCCAACTCTCACT-3Ј; CCL2 R, 5Ј-TCAT TGGGATCATCTTGCTG-3Ј; IL-6 F, 5Ј-ACCACGGCCTTCCCTACTTC-3Ј; IL-6 R, 5Ј-CTCATTTCCACGATTTCCCAG-3Ј; chemokine (C-X-C motif) ligand 10 (CXCL10) F, 5Ј-AAGTGCTGCCGTCATTTTCT-3Ј; CXCL10 R, 5Ј-T TCATCGTGGCAATGATCTC-3Ј; hypoxanthine-guanine phosphoribosyltransferase (HPRT) F, 5Ј-GCGTCGTGATTAGCGATCATC-3Ј; HPRT R, 5Ј-CTC GAGCAAGTCTTTCAGTCC-3Ј. Amplification was performed using the Applied Biosystems 7300 sequence detector (Applied Biosystems, Foster City, CA). The specificity of amplification was confirmed using melting curve analysis. Data were analyzed as previously described (20) , with normalization to HPRT.
Statistical analysis. Two-tailed unpaired Student's t tests were used to analyze differences in mean values between groups. A log rank sum test was used to analyze survival curves. All results are expressed as means Ϯ standard errors of the means (SEM). Differences with P values of Ͻ0.05 were considered significant.
RESULTS

Generation and expression of IL-10-producing rJ2.2 virus.
To test the effects of increasing IL-10 levels at early times postinfection (p.i.) and at the site of infection, we used reverse genetics to develop a rJ2.2 that expressed murine IL-10 (rJ2.2-IL-10) ( Fig. 1A) . For a control, we also engineered a virus encoding an IL-10 gene with a mutated start codon and two early stop codons (rJ2.2-⌬IL-10) ( Fig. 1A) . To confirm IL-10 expression, we infected murine fibroblast 17Cl-1 tissue culture cells with rJ2.2, three different isolates of rJ2.2-IL-10, or two isolates of rJ2.2-⌬IL-10. IL-10 mRNA was detected in cells infected with rJ2.2-IL-10 or rJ2.2-⌬IL-10 but not rJ2.2 (data not shown). Sequence analysis confirmed the presence of the full-length IL-10 gene in rJ2.2-IL-10-infected cells and a mutated IL-10 gene in the cells infected with rJ2.2-⌬IL-10. We then examined infected cell supernatants for IL-10 protein expression by ELISA at 24 h p.i. As shown in Fig. 1B , all rJ2.2-IL-10 isolates expressed similarly high levels of IL-10, while the rJ2.2-⌬IL-10 isolates and wild-type rJ2.2 produced no IL-10 protein.
To determine whether insertion of IL-10 or ⌬IL-10 affected virus replication, we examined the kinetics of virus growth in 17Cl-1 cells. rJ2.2-IL-10, rJ2.2-⌬IL-10, and rJ2.2 replicated with similar kinetics, demonstrating no effect of IL-10 expression on virus replication (Fig. 1C) .
Exogenous IL-10 expression in rJ2.2-IL-10-infected B6 mice. In order to examine the expression of recombinant IL-10 in vivo, B6 mice were infected with 1,000 PFU of either rJ2.2-IL-10 or rJ2.2-⌬IL-10. Levels of infectious virus are maximal at days 3 to 5 p.i. in rJ2.2-infected B6 mice, with clearance occurring by day 14 p.i. (4) . As seen in Fig. 2A , robust production of IL-10 protein was detected in the CNS of rJ2.2-IL-10-infected B6 mice. IL-10 levels were 10 fold higher in rJ2.2-IL-10-infected mice than in rJ2.2-⌬IL-10-infected mice at day 2 p.i., although the levels were very similar by day 7 p.i. By this time p.i., infectious virus is largely cleared and most IL-10 is derived from the host, with IL-10 levels similar to those reported previously (15, 41) . Of note, serum IL-10 levels in all mice were below the limit of detection (32.0 pg/ml).
Exogenous genes inserted into recombinant mouse hepatitis virus are sometimes deleted during murine infection (9, 17) . Therefore, we examined the brains of rJ2.2-IL-10-and rJ2.2-⌬IL-10-infected mice at day 7 p.i. by RT-PCR to assess retention of the IL-10 or ⌬IL-10 gene. Only PCR products corresponding to intact IL-10 genes were detected (Fig. 2B ), suggesting that significant deletion had not occurred and that IL-10 expression in vivo was stable for at least 7 days.
Virus gene-encoded IL-10 is protective in rJ2.2-infected B6 mice. Next, we determined whether IL-10 expressed in rJ2. However, this decrease in clinical disease in rJ2.2-IL-10-infected B6 mice was associated with diminished ability to control virus replication. Virus titers were significantly higher at days 5 and 7 p.i. in rJ2.2-IL-10-infected B6 mice than in rJ2.2-⌬IL-10-infected B6 mice, although differences diminished by day 10 p.i. (Fig. 3D) . Virus was cleared from most mice by day 14 p.i. Immunopathological disease in rJ2.2-infected mice is manifested by myelin destruction, which is maximal at 2 to 3 weeks after infection and occurs during the process of virus clearance (42) . To determine whether increased IL-10 expression, by dampening the immune response, diminished myelin destruction, we examined infected spinal cords at day 21 p.i. The level of demyelination in rJ2.2-IL-10-infected mice was significantly decreased compared to those that were infected with rJ2.2-⌬IL-10 ( Fig. 3E to G) .
Inflammatory cell infiltration into the CNS is diminished while Treg frequency and numbers are increased in B6 mice infected with rJ2.2-IL-10. To explore the basis of diminished clinical disease and demyelination in rJ2.2-IL-10 mice, we initially compared the composition of the cellular infiltrates pres-ent in rJ2.2-IL-10-and rJ2.2-⌬IL-10-infected B6 mice ( Fig. 4) . At days 3 and 5 p.i., there was a significantly decreased number of macrophages and polymorphonuclear leukocytes (PMNs) in the CNS of B6 mice infected with rJ2.2-IL-10 compared to mice infected with rJ2.2-⌬IL-10 ( Fig. 4B and C) . The total numbers of CD4 and CD8 T cells were decreased at days 5 and 7 when mice infected with rJ2.2-IL-10 and rJ2.2-⌬IL-10 were compared, though only the difference in CD4 T cell numbers achieved statistical significance at day 5 p.i. (Fig. 4D and E) .
To assess the effects of IL-10 expression on the numbers of virus-specific CD4 and CD8 T cells, we used intracellular cytokine staining for IFN-␥ after stimulation with peptides corresponding to immunodominant CD4 (M133) and CD8 (S510) T cell epitopes. Lower numbers but not frequencies of M133specific CD4 and S510-specific CD8 T cells were detected at day 7 after infection with rJ2.2-IL-10 compared to rJ2.2-⌬IL-10 ( Fig. 4F and G) , reflecting differences in the total numbers of infiltrating inflammatory cells.
IL-10 has a role in maintaining Treg function (34) and Foxp3 ϩ Tregs have important anti-inflammatory effects in rJ2.2-infected mice (40) . To determine whether virus geneencoded IL-10 enhanced the number of Tregs in the infected CNS, we examined the numbers and frequency of these cells at day 7 p.i. Both frequency and numbers of Tregs were increased in rJ2.2-IL-10-infected mice compared to those infected with rJ2.2-⌬IL-10, suggesting that IL-10 has both direct and indirect on March 11, 2015 by guest http://jvi.asm.org/ resulted in lower levels of expression of CD40, CD86, and MHC class II antigen on microglia (Fig. 6 ). Virus gene-encoded IL-10 expression also diminished the levels of several proinflammatory chemokines and cytokines in the brains of rJ2.2-IL-10-infected mice compared to rJ2.2-⌬IL-10-infected mice. At day 4 p.i., there were decreased mRNA levels of TNF, IL-6, CCL2, and CXCL10 in the brains of rJ2.2-IL-10-infected mice (Fig. 7A ). Decreased mRNA levels corresponded to decreased protein levels of TNF, IL-6, and CCL2 as measured by ELISA (Fig. 7C ). By day 10 p.i., no differences in brain chemokine or cytokine levels were detected (Fig. 7B) . Concomitant with decreased cytokine/chemokine levels in the rJ2.2-IL-10infected brain, the levels of TNF, CCL2, and IL-6 were statistically lower in draining cervical lymph nodes (CLN) at days 4 p.i. (Fig. 7D) , with TNF mRNA levels remaining lower at day 10 p.i. (Fig. 7E ). Viral gene-encoded IL-10 is protective in rJ2.2-IL-10-infected IL-10 ؊/؊ mice. B6 mice express IL-10 during both acute and chronic phases after rJ2.2 infection (41) , and this host-derived IL-10 may act to enhance the effects of viral IL-10. To determine whether IL-10 expressed solely in the first few days after infection was sufficient for improved clinical outcomes and diminished demyelination, we infected IL-10 Ϫ/Ϫ mice with 1,000 PFU of rJ2.2-IL-10 or rJ2.2-⌬IL-10. rJ2.2-IL-10-infected IL-10 Ϫ/Ϫ mice had a significant increase in survival compared to mice infected with rJ2.2-⌬IL-10 (P ϭ 0.02; Fig. 8A ). The effects on survival were so dramatic, with few mice surviving, that all further studies in IL-10 Ϫ/Ϫ mice were performed after infection with 500 PFU. IL-10 Ϫ/Ϫ mice infected with this amount of rJ2.2-IL-10 had 100% survival (Fig. 8A ) and significantly decreased weight loss (Fig. 8B , days 8 to 10 and 14 to 21, P Ͻ 0.05) and clinical scores (Fig. 8C , days 10 to 16, P Ͻ 0.05) compared to mice infected with rJ2.2-⌬IL-10. IL-10 protein was detected in the brains of rJ2.2-IL-10infected IL-10 Ϫ/Ϫ mice until day 7 p.i., but by day 10 p.i., the levels were undetectable in most mice (Fig. 8D ). This decrease in IL-10 expression reflected virus clearance, because as in infected B6 mice, IL-10 was not deleted from rJ2.2-IL-10-or rJ2.2-⌬IL-10-infected IL-10 Ϫ/Ϫ mice by day 7 p.i. (Fig. 2B) . Virus clearance was more rapid in rJ2.2-⌬IL-10-infected IL-10 Ϫ/Ϫ mice than in mice infected with rJ2.2-IL-10 (Fig. 8E ). In agreement with the results shown for infected B6 mice (Fig. 3E  to G) , the amount of demyelination in mice was significantly decreased in rJ2.2-IL-10-infected mice compared to that in mice infected with rJ2.2-⌬IL-10 ( Fig. 8F) . To further delineate the minimal time of expression required for an ameliorating effect, we blocked the IL-10 receptor (IL-10R) in IL-10 Ϫ/Ϫ Other mice received isotype control antibody beginning 1 day prior to infection. Notably, antibody is able to penetrate the infected CNS as late as day 12 p.i. (28) . IL-10R blockade prior to rJ2.2-IL-10 infection resulted in more severe clinical disease, weight loss, and demyelination than was observed in mice that received control antibody or anti-IL-10R antibody beginning at day 5 p.i. (Fig. 8G to J) . Thus, IL-10 expression during only the first 5 days p.i. was sufficient to diminish evidence of myelin destruction 2 weeks later.
DISCUSSION
IL-10 is expressed maximally at early times p.i. in rJ2.2infected mice (15, 41) , yet many of its anti-inflammatory effects are manifested during the resolution phase of the infection. Here, using a recombinant rJ2.2 engineered to express IL-10, we show that IL-10 produced during the peak of virus replication results in improved outcomes and, more importantly, in diminished myelin destruction. Demyelination is first detected several days after virus clearance in rJ2.2-infected mice (42) . Consequently, these results also indicate that the immunopathological process resulting in myelin destruction is actually initiated at early stages in the host inflammatory response. Further, the same degree of protection was evident in rJ2.2-IL-10-infected IL-10 Ϫ/Ϫ mice, in which no IL-10 is made after infectious virus is cleared, confirming a critical role for IL-10 expressed at early times p.i. We demonstrated that virus-expressed IL-10 protected against weight loss, clinical disease, and mortality associated with rJ2.2-induced acute encephalomyelitis ( Fig. 3 and 8 ). Neutralization of IL-10 activity begin-ning at day 5 p.i. in rJ2.2-IL-10-infected IL-10 Ϫ/Ϫ mice did not enhance demyelination, suggesting that IL-10 functioned by diminishing the innate or very early T cell immune response. Consistent with this, the protective effect of enhanced IL-10 expression was associated with a dampened immune response, manifested by decreased levels of proinflammatory chemokines and cytokines ( Fig. 7) , decreased CNS infiltration of inflammatory cells (Fig. 4) , diminished microglial activation (Fig. 6) , and increased frequency and number of Tregs in the infected CNS ( Fig. 5 ).
Virus-specific CD4 and CD8 T cells produce nearly all of the IL-10 detected in the rJ2.2-infected CNS at day 7 p.i. (42) . The present study provides evidence, however, that the cellular source and timing of IL-10 production are not critical. T cells are not the source for virus-induced IL-10 because rJ2.2 infects oligodendrocytes, astrocytes, and microglia but not T cells (13) . Additionally, T cells maximally produce IL-10 at day 7 p.i., while virus-induced IL-10 expression is maximal at day 2 p.i. Furthermore, T cell infiltration lags behind virus as it spreads in the CNS (42; S. Perlman, unpublished observations), suggesting that the exact location of IL-10 expression is not critical. Further, our results show that IL-10 does not have to be expressed for extended periods of time to have protective effects during both the acute and resolution phases of viral encephalitis.
The concept that exogenous IL-10 is useful therapeutically to diminish immunopathological disease has been previously examined in settings of transplantation and autoimmune disease (1, 32, 33) . IL-10, delivered via adeno-associated virus or lentivirus vectors, diminishes the rate of graft rejection in several models of organ transplantation, including allogeneic heart, lung, liver, and pancreas transplants (8, 11, 19, 25) . IL-10 diminished disease severity in several autoimmune diseases, including mice with experimental autoimmune encephalomyelitis (EAE) (6, 7, 24, 47) .
Less is known about the effects of IL-10 treatment in virus infections. In the context of infection with vaccinia virus, exogenous IL-10 had small effects in immunocompetent mice, modestly decreasing NK and CD8 T cell function without affecting virus clearance or survival (22) . In another study, IL-10 was administered intranasally to mice at the time of infection with respiratory syncytial virus (14) . At 24 h p.i., significant reductions in lung pathology without effects on virus clearance were noted, although mice were not analyzed at later times p.i. Thus, exogenous IL-10 may be generally useful in virus infections, such as rJ2.2 and RSV, in which there is a substantial immunopathological component.
Although IL-10 is expressed directly at the site of rJ2.2 infection, we cannot rule out systemic effects of the virusproduced IL-10. rJ2.2 infection is confined to the CNS (13), and increased IL-10 levels were not observed in the serum (below the limit of detection of 32 pg/ml). However, we detected decreased levels of TNF and CCL2 mRNA in the draining CLN in rJ2.2-IL-10-infected mice compared to those in rJ2.2-⌬IL-10-infected mice (Fig. 7) . These decreases may have resulted from systemic IL-10 spread (at levels in the blood beneath the level of detection) or may have been an indirect consequence of diminished inflammation in the brain. This diminished inflammatory response in the CLN may have contributed to an increased number of Tregs and diminished proinflammatory cellular infiltration into the brain (Fig. 4 and 5) , amplifying the effects of the virus-produced IL-10.
In summary, we provide evidence that a relative paucity of IL-10 produced during a viral CNS infection contributes to more severe acute disease and immunopathology. The anti- on March 11, 2015 by guest http://jvi.asm.org/ inflammatory immune response is likely to be required for disease resolution in all viral encephalitides, but the details of the response may be dependent on the pathogen. For example, regulatory T cells, rather than IL-10, appear to be most important for disease resolution in cases of West Nile virus encephalitis (2, 23) . This may be related to the ability of rJ2.2 but not West Nile virus to cause demyelination. Thus, while our results suggest that IL-10 delivered early after infection may improve outcomes in some viral CNS infections, they also demonstrate the need to understand pathogen-specific encephalitis before instituting immune-modulating therapy.
